Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.61 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.58 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.58 |
| ▸ | DRD2 | P14416 | 2/20 | 0.57 |
| ▸ | DRD3 | P35462 | 1/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | HBB | P68871 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3154468 | 0.98 | ALDH1A1 (0.64) | PRMT6ALDH1A1SMN1; SMN2TDP1CYP2D6 | |
| SCHEMBL29966226 | 0.98 | ALDH1A1 (0.64) | PRMT6ALDH1A1SMN1; SMN2TDP1CYP2D6 | |
| SCHEMBL10367496 | 0.98 | ALDH1A1 (0.64) | PRMT6ALDH1A1SMN1; SMN2TDP1CYP2D6 | |
| SCHEMBL10370403 | 0.98 | ALDH1A1 (0.64) | PRMT6ALDH1A1SMN1; SMN2TDP1CYP2D6 | |
| SCHEMBL27650580 | 0.96 | PRMT6 (0.58) | PRMT6ALDH1A1SMN1; SMN2TDP1CYP2D6 | |
| SCHEMBL24556358 | 0.84 | ALDH1A1 (0.59) | ALDH1A1SMN1; SMN2TDP1DRD2DRD3 | |
| SCHEMBL10991095 | 0.84 | MEN1 (0.66) | ALDH1A1DRD2DRD3KDM4EBCL2L1 | |
| SCHEMBL10370696 | 0.84 | MC4R (0.62) | PRMT6ALDH1A1DRD2DRD3KDM4E | |
| SCHEMBL30118939 | 0.84 | NCF1 (0.66) | ALDH1A1SMN1; SMN2CYP2D6CYP2C9DRD2 | |
| SCHEMBL1928790 | 0.84 | NCF1 (0.66) | ALDH1A1SMN1; SMN2CYP2D6CYP2C9DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110724084-B | Synthesis method of (S) -3-hydroxy-1-benzylpyrrolidine | 苏州永健生物医药有限公司 | 2022-03-04 | — | — | CN | claimed |
| CN-110724084-A | Synthesis method of (S) -3-hydroxy-1-benzylpyrrolidine | 苏州永健生物医药有限公司 | 2020-01-24 | — | — | CN | claimed |
| US-20250216782-A1 | MASKING PROCESS USING SWITCHABLE POLYMER | TOKYO ELECTRON LTD (JP) | 2025-07-03 | — | — | US | disclosed |
| US-20230149398-A1 | TOPICAL PHARMACEUTICAL COMPOSITIONS COMPRISING IMIDAZO[1,2-B]PYRIDAZINE COMPOUNDS | BENEVOLENTAI BIO LIMITED (GB) | 2023-05-18 | — | — | US | disclosed |
| CN-110283118-B | Preparation method of barnidipine key intermediate | 贵州医科大学 | 2022-05-17 | — | — | CN | disclosed |
| CN-110724084-B | Synthesis method of (S) -3-hydroxy-1-benzylpyrrolidine | 苏州永健生物医药有限公司 | 2022-03-04 | — | — | CN | disclosed |
| CN-110724084-B | Synthesis method of (S) -3-hydroxy-1-benzylpyrrolidine | 苏州永健生物医药有限公司 | 2022-03-04 | — | — | CN | disclosed |
| CN-110724084-A | Synthesis method of (S) -3-hydroxy-1-benzylpyrrolidine | 苏州永健生物医药有限公司 | 2020-01-24 | — | — | CN | disclosed |
| CN-110724084-A | Synthesis method of (S) -3-hydroxy-1-benzylpyrrolidine | 苏州永健生物医药有限公司 | 2020-01-24 | — | — | CN | disclosed |
| CN-102471258-A | 3-phenoxymethylpyrrolidine compounds | THERAVANCE INC | 2012-05-23 | — | — | CN | disclosed |
| US-6887905-B2 | Treatment of depression or generalized anxiety disorder | PFIZER INC (US) | 2005-05-03 | — | — | US | disclosed |
| US-4954507-A | 1-tertiary-alkyl-substituted naphthyridine carboxylic acid antibacterial agents | BRISTOL-MYERS COMPANY (US) | 1990-09-04 | — | — | US | disclosed |
| EP-0288519-A1 | 1-TERTIARY-ALKYL-SUBSTITUTED NAPHTHYRIDINE- AND QUINOLINE-CARBOXYLIC ACID ANTIBACTERIAL AGENTS | Bristol-Myers Squibb Company (US) | 1988-11-02 | — | — | EP | disclosed |
| EP-0266576-A2 | 1-Tert-alkyl-substituted naphthyridine and quinoline carboxylic acids as antibacterial agents | Bristol-Myers Squibb Company (US) | 1988-05-11 | — | — | EP | disclosed |
| WO-1988002627-A1 | 1-TERTIARY-ALKYL-SUBSTITUTED NAPHTHYRIDINE- AND QUINOLINE-CARBOXYLIC ACID ANTIBACTERIAL AGENTS | BRISTOL-MYERS COMPANY (US) | 1988-04-21 | — | — | WO | disclosed |
| US-4694008-A | HISTAMINE H2-ANTAGONISTS | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1987-09-15 | — | — | US | disclosed |
| EP-0180298-A2 | Pyrimidine compounds | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1986-05-07 | — | — | EP | disclosed |
| EP-0150073-A1 | 3,4-Disubstituted-1,2,5-oxadiazoles having histamine H2-receptor antagonist activity | Bristol-Myers Squibb Company (US) | 1985-07-31 | — | — | EP | disclosed |
| US-4507485-A | 3,4-Disubstituted-1,2,5-oxadiazoles having histamine H2 -receptor antagonist activity | BRISTOL-MYERS COMPANY (US) | 1985-03-26 | — | — | US | disclosed |
| US-4433154-A | ANTIHISTAMINES, ANTIULCER AGENTS | SHIONOGI & COMPANY, LIMITED (JP) | 1984-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230149398-A1 | TOPICAL PHARMACEUTICAL COMPOSITIONS COMPRISING IMIDAZO[1,2-B]PYRIDAZINE COMPOUNDS | TNK2, TNIK, TNK1 | PRMT6 3647/4885ALDH1A1 3027/4885SMN1; SMN2 1472/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.